Abstract
Purpose
Blood platelet numbers are correlated to growth and aggressiveness of several tumor types, including hepatocellular carcinoma (HCC). We previously found that platelet lysates (hPLs) also stimulated growth and migration, and antagonized the growth-inhibitory and apoptotic effects of both Sorafenib and Regorafenib, two multikinase inhibitors, on three HCC cell lines. In this study, in vitro function of human epidermal growth factor (EGF) with and without Sorafenib or Regorafenib was investigated.
Methods
An ELISA kit was used to evaluate the EGF concentrations in hPLs. In vitro function of EGF was assessed with proliferation MTT test. Apoptosis assay, scratch assays, and Transwell assays were performed for apoptosis, invasion, and migration, respectively. MAPK Activation Kit was used to explore MAPK phosphorylation.
Results
EGF antagonized the growth inhibition of Regorafenib on three HCC cell lines. Regorafenib-mediated growth inhibition was blocked by 70 % when the cells were pre-treated with EGF. EGF also blocked Regorafenib-induced apoptosis, as well as Regorafenib-induced decreases in cell migration and invasion. The EGF effects were in turn antagonized by concomitant addition to the cultures of EGF receptor antagonist Erlotinib, showing that the EGF receptor was involved in the mechanisms of EGF-mediated blocking of Regorafenib effects. Erlotinib also partially blocked the effects of hPLs in antagonizing Regorafenib-mediated growth inhibition, showing that EGF was an important component of hPL actions.
Conclusions
All these results show that EGF antagonized Regorafenib-mediated growth and migration inhibition and apoptosis induction in HCC cells and reinforce the idea that microenvironment can influence cancer drug actions.
Similar content being viewed by others
References
Levin J, Conley CL (1964) Thrombocytosis associated with malignant disease. Arch Intern Med 114:497–500
Stone RL, Nick AM, McNeish IA et al (2012) Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366:610–618
Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576–590
Holmes CE, Levis JE, Ornstein DL (2009) Activated platelets enhance ovarian cancer cell invasion in acellular model of metastasis. Clin Exp Metastasis 26:653–661
Steller EJ, Raats DA, Koster J et al (2013) PDGFRB promotes liver metastasis Formation of mesenchymal-like colorectal tumor cells. Neoplasia 15:204–207
Hwang SJ, Luo JC, Li CP et al (2004) Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol 10:2472–2477
Carr BI, Guerra V (2013) Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci 58:1790–1796
Carr BI, Guerra V, Pancoska P (2012) Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma. Oncology 83:339–345
Carr BI, Guerra V (2014) Features of massive hepatocellular carcinomas. Eur J Gastroenterol Hepatol 26:101–108
Carr BI, Cavallini A, D’Alessandro R et al (2014) Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer 14:351
D’Alessandro R, Refolo MG, Lippolis C et al (2014) Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer 14:351
Refolo MG, D’Alessandro R, Lippolis C et al (2014) Modulation of doxorubicin mediated growth inhibition of hepatocellular carcinoma cells by platelet lysates. Anticancer Agents Med Chem 14:1154–1160
Buergy D, Wenz F, Groden C, Brockmann MA (2012) Tumor-platelet interaction in solid tumors. Int J Cancer 130:2747–2760
Song S, Wientjes MG, Gan Y, Au JL (2000) Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 97:8658–8663
Shen K, Cui D, Sun L, Lu Y, Han M (2012) Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression. J Cell Biochem 113:2086–2089
Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG (2010) Metformin: taking away the candy for cancer? Eur J Cancer 46(13):2369–2380
Atzori F, Traina TA, Ionta MT, Massidda B (2009) Targeting insulin-like growth factor type 1 receptor in cancer therapy. Target Oncol 4:255–266
Kina S, Phonaphonh T, Liang F et al (2013) PDGFα receptor is a mediator for cisplatin-induced Met expression. Eur J Pharmacol 699:227–232
Zhou T, Duan J, Wang Y et al (2012) Fluoxetine synergys with anticancer drugs to overcome multidrug resistance in breast cancer cells. Tumour Biol 33:1299–1306
Peer D, Dekel Y, Melikhov D, Margalit R (2004) Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 64:7562–7569
Fuchs BC, Hoshida Y, Fujii T et al (2014) Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology 59:1577–1590
Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2:329–333
Carr BI, D’Alessandro R, Refolo MG et al (2013) Effects of low concentrations of Regorafenib and Sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro. J Cell Physiol 228:1344–1350
Fan FT, Shen CS, Tao L et al (2014) PKM2 regulates hepatocellular carcinoma cell epithelial-mesenchymal transition and migration upon EGFR activation. Asian Pac J Cancer Prev 15:1961–1970
Hu Z, Du J, Yang L et al (2012) GEP100/Arf6 is required for epidermal growth factor-induced ERK/Rac1 signaling and cell migration in human hepatoma HepG2 cells. PLoS One 7:e38777
Schallmoser K, Bartmann C, Rohde E et al (2007) Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 47:1436–1446
Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A (2004) An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signaling in hepatocarcinogenesis and in the resistance of HCC cells against drug-induced apoptosis. Biochem Pharmacol 68:1003–1015
Liang C, Chen W, Zhi X (2013) Serotonin promotes the proliferation of serum-deprived hepatocellular carcinoma cells via upregulation of FOXO3a. Mol Cancer 9:12–14
French DM, Lin BC, Wang M et al (2012) Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 7:e36713
Radziwon-Balicka A, Medina C, O’Driscoll L et al (2012) Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. Br J Pharmacol 167:787–804
Gilbert LA, Hemann MT (2011) Chemotherapeutic resistance: surviving stressful situations. Cancer Res 71:5062–5066
Tian X, Hao K, Qin C, Xie K, Xie X, Yang Y (2013) Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer. Dig Dis Sci 58:2705–2712
Huang P, Xu X, Wang L, Zhu B, Wang X, Xia J (2014) The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment. J Cell Mol Med 18:218–230
Carr BI, Cavallini A, Lippolis C et al (2013) Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol 228:292–297
D’Alessandro R, Refolo MG, Lippolis C et al (2013) Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemother Pharmacol 72:869–877
Acknowledgments
This work was supported by Italian Ministry of Public Health.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Rosalba D’Alessandro and Maria Grazia Refolo have equally contributed.
Professor Brian Irving Carr is on sabbatical leave.
Rights and permissions
About this article
Cite this article
D’Alessandro, R., Refolo, M.G., Lippolis, C. et al. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor. Cancer Chemother Pharmacol 75, 1237–1245 (2015). https://doi.org/10.1007/s00280-015-2751-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-015-2751-6